Medical Device News Magazine

Operation Warp Speed Leader Tapped as Panther Life Sciences’ New R&D Chief | The Appointment of Dr Matthew Hepburn to Expand Panther’s Leadership For Next Generation Immune-Mediated Therapies. In this role, Dr Martin Hepburn will drive Panther’s strategic commitment to commercialize its patented MAP technology, with a primary focus on reducing time-to-market and delivering the first commercial product to customers within the next two years. https://lnkd.in/eNqgeCqP

The Dangers of Undiagnosed Sleep Apnea: How At-Home Diagnostics Is Revolutionizing Detection and Enabling Life-Saving Treatment. By R. Kirk Huntsman, Chairman and CEO, Co-Founder of Vivos Therapeutics. Discover how at-home diagnostics are transforming the detection of undiagnosed #sleepapnea and enabling essential treatments. Read his views at https://lnkd.in/e9dVcCZw

3/19/25: A new era in #PTSD treatment is on the horizon, ushering in drug-free and trauma-free solutions. Dr. Aron Tendler, MD, Chief Medical Officer of GrayMatters Health, delves into innovative approaches that rely on the power of the brain. Discover how cutting-edge medical devices pave the way for hope and recovery in PTSD therapy. Read what Dr. Tendler has to say: https://lnkd.in/eXvxwX_H

3/19/25: City of Hope Opens Trial to Test Bone Medication for Early Type 1 Diabetes Treatment. “This is an exciting new application of a known medication that, in addition to potentially protecting and/or expanding the beta cells that remain in early type 1 diabetes patients, might also be able to help other patients with diabetes to increase beta cell number and/or function,” said Fouad R. Kandeel, M.D., Ph.D., the Arthur D. Riggs Distinguished Chair in Diabetes & Metabolism Research at City of Hope and the trial’s co-principal investigator. “We are actively working to enroll qualified patients and look forward to seeing where this trial leads us.” More details can be found at https://lnkd.in/gEXt73QB

3/19/25: Exciting news from MedCognition, Inc.! 🚀 Our Extended Reality (XR) Medical Simulation Training Technology has just been granted a Broad Method Patent by the USPTO. 🏥 Integrated into their PerSim® medical education and training platform, this innovative XR-based technology enhances training effectiveness by offering a secure and realistic environment mirroring actual patient interactions. 🩺 Students can now hone their clinical abilities and enhance readiness by engaging in real-world scenario simulations. 🔬 #MedTech #MedicalSimulation #TrainingInnovation More on this at https://lnkd.in/e2b56yiU

3/19/25: REGENXBIO has released encouraging biomarker data from the AFFINITY DUCHENNE® Trial of RGX-202 Gene Therapy. RGX-202, currently in a pivotal phase trial, stands out as the sole next-generation gene therapy for Duchenne. The latest findings from the age 1-3 group further enhance the positive safety and efficacy record observed in patients aged 4 and above. Dr. Steve Pakola, REGENXBIO's Chief Medical Officer, emphasized the versatility of RGX-202 in potentially benefiting a broad spectrum of patients across various age groups. Read more at https://lnkd.in/esWGPN-f

3/19/25: Published online on March 19 in the journal Nature, a recent study delves into the fascinating science behind the phrase "Polly Want a Cracker." The research focuses on mapping the activity of a specific group of nerve cells in a bird's brain known as the central nucleus of the anterior arcopallium (AAC). This area plays a pivotal role in influencing the muscles in the bird's vocal organ. #speechdisorder Details at https://lnkd.in/ed8Cntaa

3/19/25: CharmHealth Elevates Patient Care With Charm AI Scribe. Charm AI Scribe captures the natural dialogue between the patient and provider during a visit and transcribing it in real-time. Details at https://lnkd.in/ejXufWhe

3/19/25: Terumo Neuro commemorates 15 years of the WEB Device, a transformative innovation in aneurysm treatment. Carsten Schroeder, President and CEO of Terumo Neuro, reflects on this milestone, emphasizing the device's pivotal role in revolutionizing neurovascular care. The WEB device has not only established a new treatment standard but has also significantly impacted patient outcomes by streamlining procedures and minimizing device requirements. With a track record of 15 years of clinical success, WEB continues to elevate neurovascular care, embodying Terumo Neuro's dedication to collaboration with global medical experts for ongoing innovation in the field. #NeurovascularCare #Innovation #WEBDevice #AneurysmTreatment - details at https://lnkd.in/emFuawe8

3/19/25: Myant introduces Care360: AI-Powered Precision Cardiac Assessments for Patients and Physicians. Dr. Yaariv Khaykin, Chief Medical Officer at Myant, emphasizes the need to raise awareness about atrial fibrillation, a common arrhythmia linked to stroke, heart failure, and mortality. He highlights the impact of atrial fibrillation on quality of life and productivity, stressing that many individuals may be unaware they have it. Myant Care360 offers direct atrial fibrillation assessment referrals, granting access to specialized care and early intervention. These strategies, validated in randomized studies, have demonstrated the potential to slow or reverse the progression of atrial fibrillation. More at https://lnkd.in/ePUDgUXz